KRRO
Q3 2026 EPS Estimate
$-1.34
Aug 11, 2026 · Reports before open
Revenue Estimate
$214,286

Analyst Sentiment

Wall St. Consensus
Buy
11 analysts·Moderate coverage
73
Score
10 Buy (91%)1 Hold (9%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1091%
Hold
19%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$10.00
-22.7%
Consensus
$22.00
+70.0%
Bull
$30.00
+131.8%
12-Month Target Range11 analysts
$10.00$22.00$30.00
Current $12.94Consensus
Current Price
$12.94
Upside to Consensus
$9.06

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-61.90%
EPS
FY2028
Rev+530.00%
EPS
FY2029
Rev+1097.19%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$562,500$214,286$1M$16M$44M
Low$562,500$214,286$1M$16M$44M
High$562,500$214,286$1M$16M$44M
EBITDA Avg$-112,499$-42,857$-269,999$-3M$-9M
Low$-112,499$-42,857$-269,999$-3M$-9M
High$-112,499$-42,857$-269,999$-3M$-9M
EBIT Avg$-112,499$-42,857$-269,999$-3M$-9M
Low$-112,499$-42,857$-269,999$-3M$-9M
High$-112,499$-42,857$-269,999$-3M$-9M
Net Income Avg$-49M$-44M$-51M$-54M$-53M
Low$-65M$-59M$-73M$-54M$-53M
High$-33M$-29M$-28M$-54M$-53M
EPS Avg$-5.42$-5.20$-5.25$-5.80$-5.60
Low$-6.89$-6.33$-7.81$-5.80$-5.60
High$-3.51$-3.08$-2.94$-5.80$-5.60
Analysts (Rev / EPS)7 / 96 / 87 / 83 / 66 / 6
Quarterly
MetricQ2 2026Q3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$214,286$214,286$214,286$500,000
Low$214,286$214,286$214,286$500,000
High$214,286$214,286$214,286$500,000
EBITDA Avg$-42,857$-42,857$-42,857$-99,999
Low$-42,857$-42,857$-42,857$-99,999
High$-42,857$-42,857$-42,857$-99,999
EBIT Avg$-42,857$-42,857$-42,857$-99,999
Low$-42,857$-42,857$-42,857$-99,999
High$-42,857$-42,857$-42,857$-99,999
Net Income Avg$-16M$-15M$-15M$-16M$-17M$-17M$-17M
Low$-21M$-19M$-15M$-16M$-17M$-17M$-17M
High$-7M$-7M$-15M$-16M$-17M$-17M$-17M
EPS Avg$-1.34$-1.29$-1.32$-1.41$-1.44$-1.47$-1.50
Low$-1.82$-1.62$-1.32$-1.41$-1.44$-1.47$-1.50
High$-0.57$-0.61$-1.32$-1.41$-1.44$-1.47$-1.50
Analysts (Rev / EPS)5 / 75 / 72 / 32 / 3 / 2 / 2 / 2

Earnings Surprises

Recent Analyst Actions

May 19, 2026H.C. Wainwright
Korro Bio price target lowered to $15 from $20 at H.C. Wainwright
Target:$15.00
+50.5%from $9.97
Mar 13, 2026Cantor Fitzgerald
Korro Bio (KRRO) PT Raised to $22 at Cantor Fitzgerald on UCD Potential
Target:$22.00
+91.3%from $11.50
Mar 13, 2026Raymond James
Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform
Target:$23.00
+100.0%from $11.50
Feb 18, 2026Raymond James
Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy
Target:$18.00
+60.2%from $11.23
Jan 29, 2026H.C. Wainwright
Korro Bio upgraded to Buy from Neutral at H.C. Wainwright
Target:$20.00
+71.1%from $11.69
Jan 29, 2026Chardan Capital
Korro Bio upgraded to Buy from Neutral at Chardan
Target:$15.00
+28.3%from $11.69
Jan 28, 2026Piper Sandler
Korro Bio upgraded to Overweight from Neutral at Piper Sandler
Target:$30.00
+156.6%from $11.69
Jan 28, 2026William Blair
William Blair Reiterates Market Perform Rating on Korro Bio Inc. (KRRO), 'early stages of its pipeline with clinical data unlikely until 2027'
Target:$10.00
-10.5%from $11.17
Jan 28, 2026Oppenheimer
Korro Bio upgraded to Outperform from Perform at Oppenheimer
Target:$22.00
+104.8%from $10.74
Jan 27, 2026Cantor Fitzgerald
Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald
Target:$21.00
+95.5%from $10.74
Apr 16, 2025Chardan Capital
Korro Bio initiated with a Buy at Chardan
Target:$25.00
+85.7%from $13.46
Oct 21, 2024RBC Capital
Korro Bio Inc. (KRRO) PT Raised to $105 at RBC Capital
Target:$105.00
+36.5%from $76.94
May 15, 2024BMO Capital
BMO Capital Reiterates Outperform Rating on Korro Bio Inc. (KRRO)
Target:$120.00
+139.8%from $50.05
Mar 28, 2024H.C. Wainwright
Korro Bio Inc. (KRRO) PT Raised to $115 at H.C. Wainwright, 'KRRO-110 should be well-positioned'
Target:$115.00
+29.9%from $88.53
Mar 27, 2024RBC Capital
Korro Bio Inc. (KRRO) PT Raised to $90 at RBC Capital
Target:$90.00
+0.2%from $89.83
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.